Guangzhou Gloria Biosciences Co., Ltd. Report issue

For profit Phase 2 Phase 3
Founded: Guangzhou China (2016)
Status: No NME R&D (2016)

Organization Overview

First Clinical Trial
2017
NCT03713905
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Guangzhou Gloria Biosciences Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hodgkin Disease (Phase 2)

Lymphoma (Phase 2)

Neoplasms (Phase 1)

Uterine Cervical Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 7